Internationale Partnersuche

Forschung & Entwicklung Anfrage

Hungarian SME is looking for Turkish a manufacturing company of microRNA (Ribonucleic Acid) molecules and a university research group for joint Turkish-Hungarian bilateral grant application.

Country of Origin: Hungary
Reference Number: RDHU20201125002
Publication Date: 25 November 2020

Summary

A Hungarian pharma/biotechnology R&D company is developing novel microRNA therapeutic compounds for ischemic diseases, e.g. ischemic cardiac disease, such as acute myocardial infarction and post-infarction heart failure. The company seeks partners to further develop the microRNA compounds in a joint Hungarian-Turkish grant application. Turkish partners needed: microRNA manufacturing company with preferably cGMP certification, and university research group with experience in microRNA research.

Description

Acute myocardial infarction is an unmet medical need with currently no medication on the market. Only symptomatic drug treatment is available for patients with acute myocardial infarction. Ischemic heart disease including e.g. acute myocardial infarction and heart failure is still the leading cause of death worldwide with over 8,5 million deaths/year. In the 28 countries of the European Union ischemic heart disease is the 2nd cause of death with over 3,3 million deaths/year.



MicroRNAs (miRNA) are small non-coding RNA (Ribonucleic Acid) molecules regulating gene expression. miRNAs have novel therapeutic potential to treat ischemic heart disease. The Hungarian R&D company has identified and patented several cytoprotective miRNAs involved in cytoprotective mechanisms. The company is further developing novel microRNA therapeutic compounds for the treatment of acute myocardial infarction and post-myocardial infarction heart failure. 



Current development status: in vivo preclinical proof-of-concept study completed. 



The coordinator of the planned project is a Hungarian pharma/biotechnology R&D company developing novel in-house R&D projects and providing innovative preclinical and clinical R&D services since 2003. The company is a worldwide R&D service provider with opinion leader scientific management. As development of the miRNA therapeutic has reached preclinical proof of concept stage, the coordinator company is now preparing for further fundraising and co-development under a joint Hungarian-Turkish grant application. 



The project will be carried out by a small consortium of 4 partners. The Hungarian university will perform in vivo tests of miRNA compounds in cooperation with the Hungarian company. 



Partners sought from Turkey: 

-	manufacturing company with proven track record of small RNA synthesis, manufacturing of high-quality miRNA compounds including antagomiRs, preferably current Good Manufacturing Practice (cGMP) certified. Tasks:  manufacturing of the miRNA compounds and control/scramble compounds 

-	academic research group with outstanding scientific excellence in miRNA research. Tasks: formulation and delivery of miRNA compounds. 



Deadline for EOIs: 11 January 2021.

Advantages and Innovations

MicroRNAs are small non-coding RNA molecules regulating gene expression. miRNAs have novel therapeutic potential to treat ischemic heart disease. The Hungarian company has identified and patented several cytoprotective miRNAs involved in cytoprotective mechanisms. The Hungarian biotechnology R&D company is further developing novel microRNA therapeutic compounds for the treatment of acute myocardial infarction and post-myocardial infarction heart failure.

 

Current development status: in vivo preclinical proof-of-concept study completed in small animal model.

Requested partner

Partner 1

- Type of partner sought: Industry

- Specific area of activity of the partner: manufacturing company with proven track record of small RNA synthesis including antagomiRs, manufacturing of high-quality miRNA compounds, preferably cGMP (current Good Manufacturing Practice) certified.

- Task to be performed: During the project the partner’s tasks will include manufacturing of the miRNA compounds, antagomiRs, and control/scramble compounds. 

After the project, the partner could be involved in the commercialization of the project results as well. 



Partner 2

- Type of partner sought: Academic Research Group 

- Specific area of activity of the partner: academic research group with outstanding scientific excellence in miRNA research. 

- Task to be performed: formulation and delivery of miRNA compounds

Dissemination Countries

Turkey